

Corrigendum

Therapeutic Innovation
& Regulatory Science
2018, Vol. 52(3) 392
© The Author(s) 2018
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/2168479018771353
tirs.sagepub.com

Katz G, Pitts P. Implications of CRISPR-based germline engineering for cancer survivors. *Therapeutic Innovation & Regulatory Science*. 2017;51:672-682. (Original DOI: 10.1177/2168479017723401)

The above-referenced article was published in the issue with an incorrect article type. It was listed as a Commentary article, but should have been listed as an Editorial.